MBX Biosciences, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
MBX Biosciences, Inc. (MBX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $22.61 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2026-08-06
- MBX Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2026-06-30 was $11.18M, a 2053.37% increase year-over-year.
- MBX Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2026-03-31 was $11.44M, a 42262.96% increase year-over-year.
- MBX Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2025-12-31 was $2.85M, a 230.89% increase year-over-year.
- MBX Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2025-09-30 was $90.00K, a 8900.00% increase year-over-year.
- MBX Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2025 was $3.48M, a 185.19% increase from fiscal 2024.
- MBX Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2024 was $1.22M, a 165.65% increase from fiscal 2023.
- MBX Biosciences, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2023 was $460.00K.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month |
|---|---|---|---|---|
| 2026-06-30 | $11.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $22.61M 10-Q · filed 2026-08-06 | $25.46M derived: sum of 3 quarters · filed 2026-08-06 | $25.55M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $11.44M 10-Q · filed 2026-05-07 | $14.29M derived: sum of 2 quarters · filed 2026-05-07 | $14.38M derived: sum of 3 quarters · filed 2026-05-07 | $14.90M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $2.85M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $2.94M derived: sum of 2 quarters · filed 2026-03-12 | $3.46M derived: sum of 3 quarters · filed 2026-08-06 | $3.48M 10-K · filed 2026-03-12 |
| 2025-09-30 | $90.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $609.00K derived: sum of 2 quarters · filed 2026-08-06 | $636.00K 10-Q · filed 2025-11-06 | $1.50M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $519.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $546.00K 10-Q · filed 2026-08-06 | $1.41M derived: sum of 3 quarters · filed 2026-08-06 | $1.41M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $27.00K 10-Q · filed 2026-05-07 | $888.00K derived: sum of 2 quarters · filed 2026-05-07 | $889.00K derived: sum of 3 quarters · filed 2026-05-07 | $1.09M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $861.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $862.00K derived: sum of 2 quarters · filed 2026-03-12 | $1.06M derived: sum of 3 quarters · filed 2026-03-12 | $1.22M 10-K · filed 2026-03-12 |
| 2024-09-30 | $1.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $203.00K derived: sum of 2 quarters · filed 2025-11-06 | $361.00K 10-Q · filed 2025-11-06 | $501.00K derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $202.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $360.00K 10-Q · filed 2025-08-07 | $500.00K derived: sum of 3 quarters · filed 2025-08-07 | |
| 2024-03-31 | $158.00K 10-Q · filed 2025-05-12 | $298.00K derived: sum of 2 quarters · filed 2025-05-12 | ||
| 2023-12-31 | $140.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | $460.00K 10-K · filed 2025-03-17 | ||
| 2023-09-30 | $320.00K 10-Q · filed 2024-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |